Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

“…The administration of the prophylactic treatment to all the patients included in the cohort could have prevented 14 VTE with a nonsignificant higher risk of major bleeding events. 39 The difference in the AUC for the ONCOTHROMB score in the ONCOTHROMB 12-01 and Vienna-CATS populations was not significant (0.781 v 0.686; P 5 .070). Figure 1 shows the AUC for ONCOTHROMB score and for Khorana score both in ONCOTHROMB 12-01 and Vienna-CATS populations.…”

“…The administration of prophylactic treatment to all the patients included in the cohort would have helped prevent 30 VTE events with a nonsignificant higher risk of major bleeding events. 39 …”

“…Under the criteria of drug effectiveness used (ie, a reduction in cancer-associated VTE of 46%), the Khorana The administration of prophylactic treatment to all the patients included in the cohort would have helped prevent 30 VTE events with a nonsignificant higher risk of major bleeding events. 39 Validation of the ONCOTHROMB Score…”

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

“…The administration of the prophylactic treatment to all the patients included in the cohort could have prevented 14 VTE with a nonsignificant higher risk of major bleeding events. 39 The difference in the AUC for the ONCOTHROMB score in the ONCOTHROMB 12-01 and Vienna-CATS populations was not significant (0.781 v 0.686; P 5 .070). Figure 1 shows the AUC for ONCOTHROMB score and for Khorana score both in ONCOTHROMB 12-01 and Vienna-CATS populations.…”

“…The administration of prophylactic treatment to all the patients included in the cohort would have helped prevent 30 VTE events with a nonsignificant higher risk of major bleeding events. 39 …”

“…Under the criteria of drug effectiveness used (ie, a reduction in cancer-associated VTE of 46%), the Khorana The administration of prophylactic treatment to all the patients included in the cohort would have helped prevent 30 VTE events with a nonsignificant higher risk of major bleeding events. 39 Validation of the ONCOTHROMB Score…”

Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS)

“…Historically, aspirin is used for primary VTE prevention in such patients and is recommended in the guidelines [18,19]. Indeed, a Cochrane review found a non-significant 49% reduction in the risk of VTE with LMWH compared with aspirin (HR, 0.51; 95% CI,0.22–1.17) [20]. However, recent observational cohorts, including the Melisse study, showed high rates of VTE with current clinical practice [21].…”

Primary venous thromboembolism prophylaxis in patients with solid tumors

“…In the year since our initial abstraction and analysis, similar studies have found equivalent results to the question of primary thrombosis prevention in outpatients with cancer. Most recently, in a meta-analysis by DiNisio et al, including patients with all types of cancer the use of preventive low molecular weight heparin (LMWH) was associated with a reduction in venous thromboembolism (VTE) (RR 0.53, 95 % CI 0.38-0.75) [2]. This estimate is concordant with ours (OR 0.53; 95 %CI 0.41-0.70) despite small differences in methodology [1].…”

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

“…The administration of the prophylactic treatment to all the patients included in the cohort could have prevented 14 VTE with a nonsignificant higher risk of major bleeding events. 39 The difference in the AUC for the ONCOTHROMB score in the ONCOTHROMB 12-01 and Vienna-CATS populations was not significant (0.781 v 0.686; P 5 .070). Figure 1 shows the AUC for ONCOTHROMB score and for Khorana score both in ONCOTHROMB 12-01 and Vienna-CATS populations.…”

“…The administration of prophylactic treatment to all the patients included in the cohort would have helped prevent 30 VTE events with a nonsignificant higher risk of major bleeding events. 39 …”

“…Under the criteria of drug effectiveness used (ie, a reduction in cancer-associated VTE of 46%), the Khorana The administration of prophylactic treatment to all the patients included in the cohort would have helped prevent 30 VTE events with a nonsignificant higher risk of major bleeding events. 39 Validation of the ONCOTHROMB Score…”

Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS)

“…Historically, aspirin is used for primary VTE prevention in such patients and is recommended in the guidelines [18,19]. Indeed, a Cochrane review found a non-significant 49% reduction in the risk of VTE with LMWH compared with aspirin (HR, 0.51; 95% CI,0.22–1.17) [20]. However, recent observational cohorts, including the Melisse study, showed high rates of VTE with current clinical practice [21].…”

Primary venous thromboembolism prophylaxis in patients with solid tumors

“…In the year since our initial abstraction and analysis, similar studies have found equivalent results to the question of primary thrombosis prevention in outpatients with cancer. Most recently, in a meta-analysis by DiNisio et al, including patients with all types of cancer the use of preventive low molecular weight heparin (LMWH) was associated with a reduction in venous thromboembolism (VTE) (RR 0.53, 95 % CI 0.38-0.75) [2]. This estimate is concordant with ours (OR 0.53; 95 %CI 0.41-0.70) despite small differences in methodology [1].…”

A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts

“…The administration of the prophylactic treatment to all the patients included in the cohort could have prevented 14 VTE with a nonsignificant higher risk of major bleeding events. 39 The difference in the AUC for the ONCOTHROMB score in the ONCOTHROMB 12-01 and Vienna-CATS populations was not significant (0.781 v 0.686; P 5 .070). Figure 1 shows the AUC for ONCOTHROMB score and for Khorana score both in ONCOTHROMB 12-01 and Vienna-CATS populations.…”

“…The administration of prophylactic treatment to all the patients included in the cohort would have helped prevent 30 VTE events with a nonsignificant higher risk of major bleeding events. 39 …”

“…Under the criteria of drug effectiveness used (ie, a reduction in cancer-associated VTE of 46%), the Khorana The administration of prophylactic treatment to all the patients included in the cohort would have helped prevent 30 VTE events with a nonsignificant higher risk of major bleeding events. 39 Validation of the ONCOTHROMB Score…”

Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS)

“…Historically, aspirin is used for primary VTE prevention in such patients and is recommended in the guidelines [18,19]. Indeed, a Cochrane review found a non-significant 49% reduction in the risk of VTE with LMWH compared with aspirin (HR, 0.51; 95% CI,0.22–1.17) [20]. However, recent observational cohorts, including the Melisse study, showed high rates of VTE with current clinical practice [21].…”

Primary venous thromboembolism prophylaxis in patients with solid tumors

“…In the year since our initial abstraction and analysis, similar studies have found equivalent results to the question of primary thrombosis prevention in outpatients with cancer. Most recently, in a meta-analysis by DiNisio et al, including patients with all types of cancer the use of preventive low molecular weight heparin (LMWH) was associated with a reduction in venous thromboembolism (VTE) (RR 0.53, 95 % CI 0.38-0.75) [2]. This estimate is concordant with ours (OR 0.53; 95 %CI 0.41-0.70) despite small differences in methodology [1].…”